Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GDC-0810 in ER-positive advanced or metastatic breast cancer
NL-OMON45124Phase 2Active, not recruiting
- Sponsor
- Roche
- Start
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of brilanestrant in breast cancer (4 cohorts), sponsored by Roche. Primary endpoints: Maximum tolerated dose, Incidence of adverse events and 1 more. Started Dec 2015; status: active, not recruiting.
02
Drugs
brilanestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON45124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45124.